Ustekinumab: A Review in Moderate to Severe Crohn's Disease

Drugs
Yvette N Lamb, Sean T Duggan

Abstract

Ustekinumab (Stelara(®)) has been recently approved in the EU and the USA as intravenous induction and subcutaneous maintenance therapy for adult patients with moderately to severely active Crohn's disease who have failed or were intolerant to treatment with immunomodulators, corticosteroids or at least one tumour necrosis factor (TNF) antagonist. Ustekinumab, a monoclonal antibody to the shared p40 subunit of the proinflammatory interleukin (IL)-12 and IL-23 cytokines, has a unique mechanism of action distinct from that of TNF antagonists. In pivotal phase III trials, compared with placebo, ustekinumab induction therapy improved clinical response and remission rates in patients who had previously failed or were intolerant to conventional therapies or at least one TNF antagonist. When administered as subcutaneous maintenance therapy, ustekinumab continued to offer benefits over placebo for clinical response and remission in patients who had clinically responded to the induction therapy. Ustekinumab was generally well tolerated as both induction and maintenance therapy; serious infections and malignancies were rare. Thus, ustekinumab presents a promising alternative treatment option in patients with moderately to severely active...Continue Reading

References

Aug 22, 2006·The Journal of Immunology : Official Journal of the American Association of Immunologists·Christoph BeckerMarkus F Neurath
Sep 20, 2006·The Journal of Immunology : Official Journal of the American Association of Immunologists·Eiko ToichiKevin D Cooper
Aug 19, 2008·Gastroenterology·William J SandbornUNKNOWN Ustekinumab Crohn's Disease Study Group
Jul 13, 2011·Nature Biotechnology·Jacqueline M BensonMary A Mascelli
Oct 19, 2012·The New England Journal of Medicine·William J SandbornUNKNOWN CERTIFI Study Group
Jan 11, 2013·The British Journal of Dermatology·K A PappUNKNOWN ACCEPT Investigators
Aug 12, 2014·Gastroenterology Clinics of North America·Siddharth Singh, Darrell S Pardi
Oct 4, 2015·Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association·Pauline WilsUNKNOWN Groupe d'Etude Thérapeutique des Affections Inflammatoires du Tube Digestif
Jan 16, 2016·Therapeutic Advances in Gastroenterology·Ebby G SimonGordon W Moran
Dec 14, 2016·The New England Journal of Medicine·Brian G FeaganUNKNOWN UNITI–IM-UNITI Study Group

❮ Previous
Next ❯

Citations

Mar 8, 2018·Clinical Pharmacokinetics·Luc J J DerijksAdriaan A van Bodegraven
Oct 20, 2018·Digestive Diseases and Sciences·Miquell MillerCindy Kin
May 23, 2018·Inflammatory Bowel Diseases·Sophie RestelliniWaqqas Afif
Jun 24, 2020·Current Medical Research and Opinion·Roberta RobertiGiovambattista De Sarro
Jan 27, 2019·Current Treatment Options in Gastroenterology·Christopher MaNiels Vande Casteele
Dec 15, 2020·Epilepsia·Tracie Huey-Lin TanMastura Monif
Apr 3, 2021·SAGE Open Medical Case Reports·Steven A SvobodaJoshua D Eikenberg
Aug 14, 2020·Journal of Medicinal Chemistry·Brian S GerstenbergerStephen W Wright
Aug 21, 2021·Journal of Pediatric Gastroenterology and Nutrition·Francis S KimSofia G Verstraete

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.